| Position | Action |
|---|---|
| ATR of 5.35 (2.8% daily range) elevated for consumer staples | Position sizing discipline required; maintain existing position size without aggressive accumulation |
| Current price $189.57 with 26x TTM P/E | Do NOT initiate new capital at current levels |
| First re-engagement zone $175-180 with confirmed 50 SMA retest | Add first tranche on confirmed technical setup with positive MACD histogram flip |
| Second re-engagement zone $170-173 on 200 SMA test that holds | Add second tranche if 200 SMA ($168.51) tested and holds |
| Below $170 without confirmed constructive catalyst | No aggressive accumulation |
The bear case on PM is a rearview mirror story while the company accelerates a once-in-a-generation product transition; the stock is dramatically mispricing long-term optionality on ZYN's MRTP regulatory monopoly, Aurora capacity expansion, and expanding earnings power.
| Indicator | Value | Signal |
|---|---|---|
| Close | 189.57 | neutral |
| 10 EMA | 189.96 | neutral |
| 50 SMA | 183.27 | bullish |
| 200 SMA | 168.51 | bullish |
| RSI | 52.09 | neutral |
| MACD | 1.74 | bearish |
| MACD Signal | 2.68 | — |
| MACD Histogram | -0.94 | bearish |
| Bollinger Upper | 201.62 | bearish |
| Bollinger Middle | 189.85 | neutral |
| Bollinger Lower | 178.08 | bullish |
| ATR |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Hold PM at $189.57: collect 3.13% dividend while awaiting tiered pullback entry to $175-180 with technical confirmation
Hold PM at $189.57. The neutral analyst's tiered framework is correct — asymmetric risk of 7-12% downside ($178/$168) versus only 6% upside ($201), combined with three guidance cuts, Q2 EPS down 7.7% despite 22.1% operating income growth, and buyback pause all argue against initiating new capital. The $175-180 and $170-173 tiered entries with defined technical confirmations give the position a real path to scaling in rather than an aspirational $165 target. Maintain existing position size for dividend collection (17-year increase streak, 1.15x FCF coverage) while awaiting catalysts 4-12+ weeks out.
The $1.2B Aurora Campus is capacity-building capex, not margin-destructive capex; it's aggressive growth investment with ~2-3 year payback
↩ rebuts: “Bear says rising capex will pressure margins”
· concedes: PM trades at 26x TTM P/E and 2.45x PEG, which is premium to traditional tobacco; EV/EBITDA ~16.4x is high relative to sector average of 9-11x; The easy money in margin expansion may have been made, though margins are still expanding with ZYN capacity just coming online
PM is a 23-multiple business priced at 26x P/E, paying for perfection that keeps failing to materialize: EPS has been cut three times in 2026 and declined 7.7% YoY, the ZYN MRTP "monopoly" is a 2-3 year moat at best facing commoditization pressure, the $1.2B Aurora campus faces write-down risk if ZYN pricing deteriorates, EM litigation tail risk is material, and the risk/reward from current levels is asymmetric to the downside.
· concedes: PM is a quality business with real cash flow and reliable dividend; The smoke-free transformation story is compelling structurally; Q2 revenue, operating income, and EBITDA growth rates are genuinely strong in isolation; The 3.13% dividend yield is still above average S&P 500 yield
→ vs conservative: The $165 entry target is unrealistic, requiring a near-13% drawdown in a 0.40 beta stock after the company's strongest quarterly operating income growth in years
→ vs conservative: Buyback pause signals management confidence in growth pipeline (25%+ IRR Aurora investment) rather than valuation fear as conservative thesis asserts
→ vs conservative: Valuation premium reflects ZYN MRTP authorization and operating leverage transformation, not legacy cigarette metrics
→ vs neutral: The catalyst is already in motion: Q2 earnings delivered, ZYN MRTP granted, Aurora campus opened, and macro backdrop is supportive
| 5.35 |
| neutral |
Support: 186.51 · 183.27 · 178.08 · 171.25 | Resistance: 200.17 · 201.62 · 207.76
PM presents a polarity trade with a structurally bullish macro trend (price +12.5% above 200 SMA) but weakening momentum (negative MACD histogram, neutral RSI at 52.09). Price at 189.57 is compressing near the Bollinger middle band at 189.85, with elevated ATR of 5.35 indicating ~2.8% daily range—growth-stock volatility characteristics for this consumer staples name. Volume contraction on the recent bounce (4.26M vs 5.39M during late-July breakdown) suggests the rally is corrective, not impulsive. Key levels: support at 186.51/183.27/178.08 and resistance at 200.17/201.62/207.76. The path of least resistance leans toward choppy continuation higher until a directional catalyst emerges.
Market Cap
$295.47B
Market Cap (table)
$295.5B
P/E (TTM)
26.0x
Forward P/E
20.7x
PEG Ratio
2.45
EV/EBITDA
~16.4x
Dividend Yield
3.13%
Beta
0.40
52-Week High
$207.76
52-Week Low
$142.11
50-Day Avg Price
$183.58
200-Day Avg Price
$170.11
Revenue YoY (2025)
+7.6%
Net Revenue (2021)
$31.76B
Net Revenue (2022)
$31.76B
Net Revenue (2023)
$35.17B
Net Revenue (2024)
$37.78B
Net Revenue (2025)
$40.65B
Gross Margin (2025)
67.1%
Operating Margin (TTM)
40.0%
Net Margin (TTM)
25.6%
Operating Income (2025)
$14.89B
Operating Income (TTM)
$14.93B
Q2 2026 Operating Income YoY
+22.1%
Q2 2026 Revenue
$11.19B
Q2 2026 Gross Profit
$7.66B
Q2 2026 Operating Income
$4.53B
Q2 2026 Diluted EPS
$1.80
Q2 2026 EBITDA
$5.05B
EBITDA (2025)
$17.46B
EBITDA (TTM)
$18.02B
Net Income (2024)
$7.06B
Net Income (2025)
$11.35B
Net Income (TTM)
$10.84B
EPS (2024)
$4.53
EPS (2025)
$7.26
EPS (TTM)
$7.28
Forward EPS
$9.17
ROA
14.6%
FCF (TTM)
$9.71B
Operating Cash Flow (TTM)
$12.23B
CapEx (2025)
$1.57B
FCF (2022)
$9.73B
FCF (2023)
$7.88B
FCF (2024)
$10.77B
FCF (2025)
$10.66B
Dividends Paid (2025)
$8.62B
Dividends Paid (TTM)
$9.20B
Annual Dividend
$5.40
Buybacks (2024-2025)
$0
Total Treasury Stock
$35.5B
Total Assets
$69.2B
Total Debt
$49.1B
Cash & Equivalents
$6.0B
Net Debt
$43.1B
Total Equity
-$8.58B
Book Value Per Share
-$5.51
Goodwill & Intangibles
$27.1B
Current Ratio
0.98
Net Debt/EBITDA
2.4x
FCF/Dividend Ratio
~1.15x
FX Exposure
~75%
Strengths
Concerns
Philip Morris International is a mega-cap ($295.5B) defensive tobacco company successfully transitioning to reduced-risk smoke-free products (HEETS/TEREA for IQOS). The Q2 2026 quarter demonstrated exceptional operating leverage with 22.1% YoY operating income growth on 10.4% revenue growth, driving TTM operating margins to 40% for the first time. The company generates massive cash flow ($9.71B TTM FCF) and has raised dividends for 17+ consecutive years, though valuation at 26x TTM P/E and 2.45x PEG reflects the smoke-free transformation premium. Key risks include regulatory headwinds, FX volatility (75% non-USD revenue), and premium valuation leaving limited near-term upside. HOLD rating recommended; wait for pullback to ~$170 (200-day MA) or breakout above $208 before initiating new long position.